Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2025)

Historic Assets Average for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to $119.4 million.

  • Barinthus Biotherapeutics' Assets Average fell 3640.44% to $119.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.4 million, marking a year-over-year decrease of 3640.44%. This contributed to the annual value of $187.4 million for FY2024, which is 2266.88% down from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Assets Average of $119.4 million as of Q3 2025, which was down 3640.44% from $135.8 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Assets Average ranged from a high of $285.6 million in Q2 2022 and a low of $108.6 million during Q1 2021
  • Its 5-year average for Assets Average is $216.8 million, with a median of $222.2 million in 2023.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Assets Average surged by 16102.68% in 2022, and later tumbled by 3640.44% in 2025.
  • Barinthus Biotherapeutics' Assets Average (Quarter) stood at $268.6 million in 2021, then rose by 1.56% to $272.8 million in 2022, then dropped by 18.55% to $222.2 million in 2023, then decreased by 21.48% to $174.5 million in 2024, then crashed by 31.59% to $119.4 million in 2025.
  • Its last three reported values are $119.4 million in Q3 2025, $135.8 million for Q2 2025, and $151.2 million during Q1 2025.